Fig. 7: Targeted inhibition or degradation of BRD9 potentiates the antiproliferative effects of chemotherapy agents and targeted therapies on AML, ALL and MM.
From: BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
A Combination indices generated from combination studies investigating the effects of QA-68 or EA-89 alone or combined with chemotherapy or targeted agents against AML cell lines (left and middle panels) and ALL and MM cell lines (right panel). B Representative dose-response curves showing antiproliferative effects of chemotherapy alone, QA-68 alone, or a combination against SKM-1, RS4;11, and H929 cells. Proliferation studies shown are representative of independent studies performed at least twice for which similar results were observed.
